Genocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. Baird

Analysts at Robert W. Baird initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a note issued to investors on Monday. The firm set an “outperform” rating and a $3.00 price target on the biotechnology company’s stock. Robert W. Baird’s price target suggests a potential upside of 200.00% from the stock’s current price.

A number of other research analysts have also commented on GNCA. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Tuesday, February 6th. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $5.00 price objective on shares of Genocea Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $4.21.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded up $0.07 during midday trading on Monday, reaching $1.00. The company’s stock had a trading volume of 1,239,075 shares, compared to its average volume of 1,250,000. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51. Genocea Biosciences has a 52-week low of $0.79 and a 52-week high of $7.29. The firm has a market cap of $82.07, a price-to-earnings ratio of -0.46 and a beta of 1.55.

Several institutional investors and hedge funds have recently added to or reduced their stakes in GNCA. Schwab Charles Investment Management Inc. acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth $257,000. Rhumbline Advisers acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth $157,000. Bank of New York Mellon Corp grew its holdings in shares of Genocea Biosciences by 594.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 72,008 shares in the last quarter. Teachers Advisors LLC acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth $268,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Genocea Biosciences during the 2nd quarter worth $404,000. 12.03% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Genocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. Baird” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/12/genocea-biosciences-gnca-earns-outperform-rating-from-analysts-at-robert-w-baird.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply